37,108 Shares in Cognition Therapeutics, Inc. (NASDAQ:CGTX) Acquired by SG Americas Securities LLC

SG Americas Securities LLC acquired a new position in Cognition Therapeutics, Inc. (NASDAQ:CGTX) in the fourth quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The firm acquired 37,108 shares of the company’s stock, valued at approximately $26,000. SG Americas Securities LLC owned approximately 0.09% of Cognition Therapeutics at the end of the most recent reporting period.

Separately, Sigma Planning Corp raised its stake in shares of Cognition Therapeutics by 14.6% during the 3rd quarter. Sigma Planning Corp now owns 197,190 shares of the company’s stock valued at $92,000 after buying an additional 25,050 shares during the last quarter. 43.35% of the stock is currently owned by hedge funds and other institutional investors.

Wall Street Analyst Weigh In

Several research firms recently issued reports on CGTX. B. Riley upgraded Cognition Therapeutics from a “neutral” rating to a “buy” rating and lifted their price objective for the stock from $1.00 to $1.50 in a report on Thursday, December 19th. HC Wainwright boosted their target price on Cognition Therapeutics from $5.00 to $6.00 and gave the company a “buy” rating in a research report on Thursday, December 19th. Brookline Capital Management raised Cognition Therapeutics to a “strong-buy” rating in a research report on Monday, January 27th. Finally, Chardan Capital reiterated a “buy” rating and set a $11.00 target price on shares of Cognition Therapeutics in a research note on Thursday, December 19th. One investment analyst has rated the stock with a hold rating, five have assigned a buy rating and one has issued a strong buy rating to the company’s stock. According to data from MarketBeat.com, Cognition Therapeutics has a consensus rating of “Buy” and a consensus price target of $8.30.

Cognition Therapeutics Stock Up 0.0 %

Shares of Cognition Therapeutics stock opened at $0.59 on Friday. The stock has a market cap of $24.52 million, a PE ratio of -0.61 and a beta of 0.96. The business has a fifty day simple moving average of $0.67 and a 200-day simple moving average of $0.60. Cognition Therapeutics, Inc. has a 12 month low of $0.34 and a 12 month high of $2.95.

About Cognition Therapeutics

Cognition Therapeutics, Inc, a clinical-stage biopharmaceutical company, engages in the discovery and development of small molecule therapeutics targeting age-related degenerative diseases and disorders of the central nervous system and retina. Its lead product candidate is CT1812, an orally delivered molecule modulator designed to penetrate the blood-brain barrier and bind selectively to the S2R complex, which is in Phase 2 clinical trial for the treatment of Alzheimer's disease, as well as geographic atrophy secondary to dry age-related macular degeneration and synucleinopathies, such as dementia with Lewy bodies.